Kyocera Corporation (Tokyo:6971), a Japanese multinational ceramics and electronics manufacturer, announced on Tuesday that its US headquarters, Kyocera International Inc, has finalised an agreement with Renovis Surgical Technologies Inc (Renovis), a US-based orthopaedic and spinal medical device manufacturer and developer, to purchase the major assets of Renovis' business operations relating to artificial joint and spinal products.
Financial details of this purchase were not available.
These assets will be transferred into a new California-based company wholly owned by Kyocera International Inc, to be named Kyocera Medical Technologies Inc, in March 2019.
Currently, Kyocera manufactures medical products, including artificial joints and dental implants, primarily for the Japanese market. The US orthopaedic implant market totals approximately USD20bn, representing about 60% of the global market, with continued growth expected. To grow internationally, Kyocera obtained US FDA 510(k) clearance for its artificial hip joints and began selling them in the US in 2017.
Renovi is a market leader in 3D-printed implants and has developed a broad portfolio of innovative products for the US market, serving the needs of orthopaedic, neurological and trauma surgeons. Renovis has continued to develop and commercialise a wide range of products manufactured using its Tesera Trabecular Technology, a proprietary implant surface structure made using additive manufacturing. In addition, Renovis has developed an advanced bearing surface technology for joint replacement products.
According to Kyocera, its global strength and expansive research and development capabilities will accelerate the growth of these valuable Renovis technologies.
Also, Kyocera plans to expand its US medical equipment business through this asset purchase. The newly established company will develop high value-added products that improve patient health and quality of life through synergies between Kyocera's proprietary technologies and those purchased from Renovis.
Kyocera is a leading supplier of semiconductor packages, industrial and automotive components, electronic devices, solar power generating systems, printers, copiers and mobile phones.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval